The development of the direct renin inhibitor aliskiren: Treating hypertension and beyond

Expert Opinion on Emerging Drugs

Volumn 13, Issue 3, 2008, Pages 417-430

  Siragy, Helmy ^a   Huang, Jiqian ^a   Lieb, David C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aliskiren; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Hypertension; Mineralocorticoid receptor blocker; Renin angiotensin aldosterone system

Indexed keywords

5 CYCLOHEXYL 4 [N [3 ETHYLSULFONYL 2 (1 NAPHTHYLMETHYL)PROPIONYL]NORLEUCINAMIDO] 1 MORPHOLINO 2,3 PENTANEDIOL; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CPG 38560; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; H 142; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MINERALOCORTICOID ANTAGONIST; N BENZYLOXYCARBONYLARGINYLARGINYLPROLYLPHENYLALANYLHISTIDYLSTATINYLISOLEUCYLHISTIDYL (NEPSILON BUTYLOXYCARBONYLLYSINE) METHYL ESTER; NALPHA [3 MORPHOLINOCARBONYL 2 (1 NAPHTHYLMETHYL)PROPIONYL]HISTIDINE N [1 CYCLOHEXYLMETHYL 2 HYDROXY 3 (1 METHYL 5 TETRAZOLYLTHIO)PROPYL]AMIDE; PLACEBO; RAMIPRIL; REMIKIREN; RENIN INHIBITOR; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALSARTAN; VASODILATOR AGENT; ZANKIREN;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FACE EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HALF LIFE TIME; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; IC 50; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MEDLINE; MONOTHERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIORBITAL EDEMA; PLASMA RENIN ACTIVITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; WEAKNESS;

AMIDES; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FUMARATES; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 53549097913     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.3.417     Document Type: Review

References (78)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
3. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics: 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69-171
4. Ayanian JZ, Zaslavsky AM, Weissman JS, et al. Undiagnosed hypertension and hypercholesterolemia among uninsured and insured adults in the Third National Health and Nutrition Examination Survey. Am J Public Health 2003;93:2051-4
5. Schelleman H, Klungel OH, Kromhout D, et al. Prevalence and determinants of undertreatment of hypertension in the Netherlands. J Hum Hypertens 2004;18:317-24
6. Hall WD, Ferrario CM, Moore MA, et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 1997;313:195-209
7. Winegarden CR. From 'prehypertension' to hypertension? Additional evidence. Ann Epidemiol 2005;15:720-5
8. Elliott WJ, Black HR. Prehypertension. Nat Clin Pract Cardiovasc Med 2007;4:538-48
9. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-6
10. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7
11. Luma GB, Spiotta RT. Hypertension in children and adolescents. Am Fam Physician 2006;73:1558-68
12. Griffin JE, Ojeda SR. Textbook of endocrine physiology. 5th edition. Oxford and New York: Oxford University Press; 2004
13. Kaplan NM, Lieberman E. Kaplan's clinical hypertension. 8th edition. Philadelphia: Lippincott Williams & Wilkins; 2002
14. Elliott WJ. Systemic hypertension. Curr Probl Cardiol 2007;32:201-59
15. Jamerson K, DeQuattto V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996;101:S22-32
16. Carson P, Giles T, Higginbotham M, et al. Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 2001;24:183-90
17. Leibovitz E, Schiffrin EL. Novel drugs targeting hypertension: renin inhibitors and beyond. J Cardiovasc Pharmacol 2007;50:3-8
18. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35
19. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77
20. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
21. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
22. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9
24. Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999;33(Suppl 1):S16-20; discussion S41-3
25. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63
26. Cohn JN, Toguoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
27. Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180-3
28. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
29. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906
30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
31. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
32. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-6
33. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation 2004;109:2492-9
34. van den Meiracker AH, Man in't Veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10:803-12
35. Hanon S, Vijayaraman P, Sonnenblick EH, Le Jemtel TH. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2000;1:147-50
36. Danser All, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;46:1069-76
37. Sealey JE, Catanzaro DF, Lavin TN, et al. Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site. Am J Hypertens 1996;9:491-502
38. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996;50:1897-903
39. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27
40. Shirai H, Autieri M, Eguchi S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 2007;16:111-5
41. Cumin F, Evin G, Fehrentz JA, et al. Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 1985;260:9154-7
42. Hui KY, Carlson WD, Bernatowicz MS, Haber E. Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. J Med Chem 1987;30:1287-95
43. Boger J, Payne LS, Perlow DS, et al. Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem 1985;28:1779-90
44. Bolis G, Fung AK, Greer J, et al. Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond. J Med Chem 1987;30:1729-37
45. Wood JM, Gulati N, Forgiarini P, et al. Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 1985;7:797-803
46. Wood JM, Stanton JL, Hofbauer KG. Inhibitots of renin as potential therapeutic agents. J Enzyme Inhib 1987;1:169-85
47. Webb DJ, Manhem PJ, Ball SG, et al. A study of the renin inhibitor H142 in man. J Hypertens 1985;3:653-8
48. Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther 1994;61:325-44
49. Imai T, Miyazaki H, Hirose S, et al. Cloning and sequence analysis of cDNA for human renin precursor. Proc Natl Acad Sci USA 1983;80:7405-9
50. Blundell T, Sibanda BL, Pearl L. Three-dimensional structure, specificity and catalytic mechanism of renin. Nature 1983;304:273-5
51. Sibanda BL, Blundell T, Hobart PM, et al. Computer graphics modelling of human renin. Specificity, catalytic activity and intron-exon junctions. FEBS Lett 1984;174:102-11
52. Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504
53. Rahuel J, Priestle JP, Grutter MG. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. J Struct Biol 1991;107:227-36
54. Cohen NC. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Chem Biol Drug Des 2007;70:557-65
55. Dhanaraj V, Dealwis CG, Frazao C, et al. X- ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature 1992;357:466-72
56. Sielecki AR, Hayakawa K, Fujinaga M, et al. Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science 1989;243:1346-51
57. Maibaum J, Stutz S, Goschke R, et al. Structural modification of the P2′ position of 2,7-dialkyl-substituted 5(S)-amino- 4(S)-hydroxy-8-phenyloctanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. J Med Chem 2007;50:4832-44
58. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705
59. Wood JM, Schnell CR, Cumin F, et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26
60. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76
61. Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-28
62. Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety; and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007;47:453-60
63. Vaidyanathan S, Warren V, Yeh C, et al. Pharmacokinetics, safety; and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007;47:192-200
64. Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46:661-75
65. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP 100): comparison with enalapril. Hypertension 2002;39:E1-8
66. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43
67. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8
68. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49:276-84
69. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26
70. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9
71. Drummond W, Munger MA, Rafique Essop M, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9:742-50
72. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8
73. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55
74. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007;13(8 Suppl B):21-33
75. Recio-Mayoral A, Kaski JC, McMurray JJ, et al. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther 2007;6:459-465
76. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56
77. Butler L, Lynch C. The new renin antagonist: aliskiren. US Pharmacist 2008;33:38-42
78. Tekturna (aliskiren) package insert. East Hanover, NJ: Novartis; February 2007